Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RDC 5

Next Previous
Drug Profile

RDC 5

Alternative Names: Chroneuro™; RDC5

Latest Information Update: 04 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chronos Therapeutics
  • Developer TheraCryf
  • Class Neuroprotectants; Osteoporosis therapies
  • Mechanism of Action Autophagy stimulants; Reactive oxygen species modulators; Synuclein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Neurodegenerative disorders; Obesity

Highest Development Phases

  • Phase I Amyotrophic lateral sclerosis
  • No development reported Neurodegenerative disorders
  • Discontinued Obesity; Osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 27 Jun 2023 Phase-I clinical trials in Amyotrophic lateral sclerosis in United Kingdom (PO) (Chronos Therapeutics pipeline, March 2023)
  • 27 Mar 2023 Discontinued - Preclinical for Obesity in United Kingdom (PO)
  • 28 Jun 2020 No recent reports of development identified for preclinical development in Obesity in United Kingdom (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top